King Pharmaceuticals And Palatin Technologies Delay Immediate Plans For Phase 3 Clinical Program With Bremelanotide For Erectile Dysfunction
Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that they have delayed plans for the initiation of Phase 3 clinical trials with bremelanotide, a first in class melanocortin agonist drug candidate, for the treatment of male erectile dysfunction (ED). The decision follows responses from representatives of the U.S.
